LabCorp Introduces New Cancer Diagnostic Test
Posted on: Wednesday, 25 June 2008, 06:03 CDT
Laboratory Corporation of America Holdings has announced the availability of OvaSure, an ovarian cancer screening test to assess the presence of early stage ovarian cancer in high-risk women.
According to Laboratory Corporation of America (LabCorp), in a recent study of high risk and average risk subjects, this blood test, using six biomarkers and research conducted at Yale University School of Medicine, was shown to discriminate between disease-free women and ovarian cancer patients (stage I-IV) with high specificity (99.4%) and sensitivity (95.3%).
Additional studies performed at Yale University School of Medicine demonstrate comparable findings, the company said.
Myla Lai-Goldman, executive vice president and chief medical officer of LabCorp, said: "OvaSure is a significant addition to LabCorp's family of proteomic tests, and a major component of LabCorp's strategy to bring the latest in diagnostic technology to women's healthcare."
Source: Datamonitor
Related Articles
- Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
- Obesity Raises Risk Of Ovarian Cancer
- Women: OVARIAN CANCER: THE FACTS
- Painkillers may cut risk of ovarian cancer
- Drinking Tea Associated with Lower Risk of Ovarian Cancer
- Ovarian cancer risk lower in tea drinkers - study
- Familial Breast Cancer Doesn't Always Boost Ovarian Cancer Risk
- Increased ovarian cancer risk not found in women with breast cancer family history
- History of Endometriosis Places Women at High Risk Of Ovarian Cancer, but Pill Use Remains Protective
- Hormones May Raise Risk of Ovarian Cancer
 |
 |
User Comments (0)
RSS Feeds